Technical Analysis for GNCAQ - Genocea Biosciences Inc

Grade Last Price % Change Price Change
C 0.0016 700.00% 0.0014
GNCAQ closed up 700.0 percent on Friday, February 3, 2023, on 1.31 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Up

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
New 52 Week Closing High Bullish 700.00%
Calm After Storm Range Contraction 700.00%
Narrow Range Bar Range Contraction 700.00%
Calm After Storm Range Contraction 1500.00%
Narrow Range Bar Range Contraction 1500.00%
Calm After Storm Range Contraction 1500.00%
Narrow Range Bar Range Contraction 1500.00%
Narrow Range Bar Range Contraction 1500.00%
Narrow Range Bar Range Contraction 1500.00%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Genocea Biosciences Inc Description

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.


Classification

Keywords: Medicine Medical Specialties Biopharmaceutical U.S. Bankruptcy Court Immune System Solid Tumors Immunotherapy Cell Therapy Cancer Treatments Antigen Immunotherapies T Cell Biomolecules Novel Cancer Gen 009 Gen 011 Patient's Tumor

Is GNCAQ a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Indicators

Indicator Value
52 Week High 0.0064
52 Week Low 0.0001
Average Volume 11,579
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 0.0000
10-Day Moving Average 0.0003
Average True Range 0.0008
RSI 0.00
ADX 0.0
+DI 98.9130
-DI 0.0000
Chandelier Exit (Long, 3 ATRs) 0.0040
Chandelier Exit (Short, 3 ATRs) 0.0025
Upper Bollinger Bands 0.0000
Lower Bollinger Band 0.0000
Percent B (%b) 0.0
BandWidth 0.0000
MACD Line 0.0001
MACD Signal Line 0.0000
MACD Histogram 0.0001
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0039
Resistance 3 (R3) 0.0036 0.0026 0.0035
Resistance 2 (R2) 0.0026 0.0020 0.0027 0.0033
Resistance 1 (R1) 0.0021 0.0017 0.0024 0.0024 0.0032
Pivot Point 0.0011 0.0011 0.0012 0.0012 0.0011
Support 1 (S1) 0.0006 0.0005 0.0009 0.0009 0.0000
Support 2 (S2) -0.0004 0.0002 -0.0003 -0.0001
Support 3 (S3) -0.0009 -0.0004 -0.0003
Support 4 (S4) -0.0007